

AI in Precision Medicine Market by Application (Drug Discovery, Screening, Diagnosis, Stratification, Staging, Prognosis, Therapy Selection, Monitoring, Risk Management), Indication (Cancer, CNS, CVS), Tools (ML, NLP), & End User -Global Forecast to 2030

Market Report | 2024-12-02 | 403 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The AI in precision medicine market is projected to reach USD 3.92 billion by 2030 from USD 0.78 billion in 2024, at a CAGR of 30.7% from 2024 to 2030. The market for AI in precision medicine is propelled by the enhanced diagnostics as well as predictive analytics. Wearable devices monitor patient's imaging and other related parameters and search for signs of disease, long before it shows itself, or the outcomes of treatments. Additionally, the movement towards cheaper healthcare provision is also the other factor. AI increases the productivity of conventional diagnosis and treatment procedures; thus, it makes precision medicine cheap and widely applicable. On the contrary, factors such as costs associated with implementation, inadequate access to high-quality data and issues with data security and privacy present challenges. Furthermore, the intricate nature of incorporating AI into already existing healthcare processes including regulatory requirements may also slow down its uptake.

"Natural language processing (NLP) had the fastest growth rate in the AI in precision medicine market during the forecast period, by tools."

Natural Language Processing (NLP) is anticipated to register the highest growth rate within the AI in precision medicine market as a result of its efficiency in deriving meaning from adequate unstructured medical data which consist of clinical notes, research works, and patient records. NLP helps to integrate unstructured data with structured data helps to get a better view of patient's history and suggestions regarding customizing treatment are improved. For instance, Tempus utilizes NLP techniques in fresh oncology treatment plans to find trends in the use of electronic health records. Furthermore, NLP-based applications are used to provide concise reports and help in making decisions very fast by shifting through a lot of scientific data and literature which hastens the process of drug invention and the diagnosis of diseases. The growing implementation of EHR systems alongside the

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

rising need for precision medicine integrated solutions stimulates the market for NLP technology. Its applicability in dealing with different healthcare data and promise of better results makes it a game changer in the market.

"By end user, the healthcare providers to account for largest market share in 2023."

By end user, AI in precision medicine market is bifurcated into healthcare providers, pharmaceutical & biotechnology companies, medical device/equipment companies, research centers, academic institutes, & government organizations, and others. The healthcare providers accounted for the largest share of the market for AI in precision medicine owing to the fact that they are the foremost practitioners of the AI tools used to enhance diagnosis, treatment planning and patient outcome. Hospitals and clinics employ AI platforms for patient data analysis, therapeutic mapping, and improving the quality of decision making. The current rampant deployment of the AI technology in the fields of medical imaging, genomics and custom care provision has made it possible for providers to give customized therapies in a quick and effective manner. In addition, the rising expenditure on AI solutions and the increasing demand for efficient and high quality healthcare systems are two factors that facilitate penetration of the market by healthcare providers.

"Asia Pacific is estimated to register the highest CAGR over the forecast period."

The AI in precision medicine market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific's AI in precision medicine market is projected to register highest CAGR during the forecast period due to enhanced allocation of resources towards healthcare infrastructure facilities, promotion of adoption of AI technology, and growing initiatives in genomic research. Countries like China, Japan and India are turning towards advanced technologies like Artificial Intelligence to transform the health care systems in these nations, due to government and private organization efforts. At the same time, the aging population creates a high demand for precision therapeutics, especially for oncology and chronic illness management, which also promotes growth in this region. In addition, an influx of both global and local companies specializing in the technology in the region, stimulates speed of innovation and use of the technology.

Breakdown of supply-side primary interviews by company type, designation, and region:

- By Company Type: Tier 1 (40%), Tier 2 (35%), and Tier 3 (25%)
- By Designation: Managers (40%), Directors (35%), and Others (25%)
- By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%) and Middle East Africa (5%)

List of Companies Profiled in the Report:

- o NVIDIA Corporation (US)
- o Google, Inc. (US)
- o Microsoft (US)
- o IBM (US)
- o Illumina, Inc. (US)
- o Exscientia (UK)
- o Insilico Medicine (US)
- o GE Healthcare (US)
- o Tempus AI, Inc. (US)
- o Siemens Healthineers AG (Germany)
- o BioXcel Therapeutics, Inc. (US)
- o BenevolentAI (UK)
- o PathAI, Inc. (US)
- o Guardant Health (US)
- o GRAIL, Inc. (US)
- o FOUNDATION MEDICINE, INC. (US)
- o FLATIRON HEALTH (US)
- o Proscia Inc. (US)
- o DEEP GENOMICS. (Canada)
- o Verge Genomics (US)
- o Predictive Oncology (US)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

o Paige AI, Inc. (US)
o Densitas Inc. (Canada)
o Zephyr AI (US)
o Iktos (France)

Research Coverage:

This research report categorizes the AI in precision medicine market by application (drug discovery & development, diagnostics & screening, and therapeutics), therapeutic area (oncology, rare diseases, infectious diseases, neurology, cardiology, haematology, and others), component (hardware, software, and services), tools (machine learning, natural language processing (NLP), context-aware processing and computing, computer vision, image analysis (including optical character recognition), and others), deployment (cloud-based model, on-premise model, and hybrid model), end user (healthcare providers, pharmaceutical & biotechnology companies, medical device/equipment companies, research centers, academic institutes, & government organizations, and others) and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the AI in precision medicine market. A thorough analysis of the key industry players has been done to provide insights into their business overview, offerings, and key strategies such as acquisitions, collaborations, partnerships, mergers, product/service launches & enhancements, and approvals in the AI in precision medicine market. Competitive analysis of upcoming startups in the AI in precision medicine market ecosystem is covered in this report.

Reasons to Buy the Report

The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall AI in precision medicine market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

- Analysis of key drivers: (Rising Demand for Personalized Healthcare), restraints (Limited access to high-quality data), opportunities (Expanding genomic research), and challenges (Regulatory and ethical complexities) influencing the growth of the AI in precision medicine market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the AI in precision medicine market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the AI in precision medicine market across varied regions.
- Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the AI in precision medicine market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players such as NVIDIA Corporation (US), Google, Inc. (US), Microsoft (US), IBM (US), Illumina, Inc. (US), Exscientia (UK), etc. among others in AI in precision medicine market.

Table of Contents:

1	INTRODUCTION	32
1.1	STUDY OBJECTIVES	32
1.2	MARKET DEFINITION	32
1.3	STUDY SCOPE	33
1.3.1	MARKETS COVERED & REGIONAL SCOPE	33
1.3.2	INCLUSIONS & EXCLUSIONS	34
1.3.3	YEARS CONSIDERED	36

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

1.4	CURRENCY CONSIDERED	36
1.5	STAKEHOLDERS	36
2	RESEARCH METHODOLOGY	38
2.1	RESEARCH DATA	38
2.1.1	SECONDARY DATA	39
2.1.1.1	Key data from secondary sources	40
2.1.2	PRIMARY DATA	40
2.1.2.1	Key data from primary sources	42
2.2	MARKET SIZE ESTIMATION	44
2.3	MARKET SHARE ESTIMATION	47
2.4	DATA TRIANGULATION	48
2.5	RESEARCH ASSUMPTIONS	49
2.6	LIMITATIONS	49
2.6.1	METHODOLOGY-RELATED LIMITATIONS	49
2.6.2	SCOPE-RELATED LIMITATIONS	49
2.7	RISK ASSESSMENT	50
3	EXECUTIVE SUMMARY	51
4	PREMIUM INSIGHTS	57
4.1	ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET OVERVIEW	57
4.2	ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY REGION	58
4.3	NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER & REGION	59
4.4	ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: GEOGRAPHIC SNAPSHOT	60
4.5	ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET: DEVELOPED VS. EMERGING MARKETS	60
5	MARKET OVERVIEW	61
5.1	INTRODUCTION	61
5.2	MARKET DYNAMICS	61
5.3	MARKET DYNAMICS	62
5.3.1	DRIVERS	62
5.3.1.1	Increase in investments in R&D and rise in demand for personalized medication	62
5.3.1.2	Advancements in genomic research and data availability	64
5.3.1.3	Growth in cross-industry collaborations and partnerships	64
5.3.1.4	Role of regulatory landscape in driving AI adoption in healthcare	66
5.3.2	RESTRAINTS	68
5.3.2.1	Increase in data breach concerns	68
5.3.2.2	High cost of implementation of precision medicine solutions	70
5.3.2.3	Accuracy challenges in AI adoption for healthcare	71
5.3.3	OPPORTUNITIES	71
5.3.3.1	Role of predictive analytics in advancing AI for healthcare	71
5.3.3.2	Leveraging research pipelines and new drug development for AI in healthcare	72
5.3.4	CHALLENGES	73
5.3.4.1	Impact of fairness and bias on AI in healthcare	73
5.3.4.2	Interoperability challenges due to complexity of AI solutions	74
5.4	TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES	74
5.5	INDUSTRY TRENDS	75
5.5.1	AI'S GROWING ROLE IN PATIENT-SPECIFIC DATA INTEGRATION AND ANALYSIS	75
5.5.2	ADVANCEMENTS IN AI-POWERED PREDICTIVE ANALYTICS FOR TREATMENT OPTIMIZATION	76

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.6	ECOSYSTEM ANALYSIS	76
5.7	VALUE CHAIN ANALYSIS	79
5.8	TECHNOLOGY ANALYSIS	80
5.8.1	KEY TECHNOLOGIES	80
5.8.1.1	Predictive analytics	80
5.8.1.2	Neural networks	81
5.8.1.3	Knowledge graphs	81
5.8.1.4	Cell and gene therapies	81
5.8.1.5	AI-driven single-cell analysis	82
5.8.2	COMPLEMENTARY TECHNOLOGY	82
5.8.2.1	High-performance computing (HPC)	82
5.8.2.2	Next-generation sequencing	82
5.8.2.3	Real-world evidence/Real-world data	83
5.8.2.4	EHR Integration	83
5.8.2.5	Digital health platforms	84
?		
5.8.3	ADJACENT TECHNOLOGIES	84
5.8.3.1	Cloud computing	84
5.8.3.2	Blockchain technology	84
5.8.3.3	Internet of Things (IoT) and wearables	85
5.8.3.4	Robotics and automation	85
5.8.3.5	3D printing for personalized implants and devices	85
5.9	REGULATORY ANALYSIS	86
5.9.1	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	86
5.9.2	REGULATORY SCENARIO	89
5.10	PRICING ANALYSIS	93
5.10.1	INDICATIVE PRICING FOR KEY PLAYERS	93
5.10.2	INDICATIVE PRICE OF KEY COMPONENTS, BY REGION	94
5.11	PORTER'S FIVE FORCES ANALYSIS	95
5.11.1	THREAT OF NEW ENTRANTS	96
5.11.2	THREAT OF SUBSTITUTES	96
5.11.3	BARGAINING POWER OF SUPPLIERS	96
5.11.4	BARGAINING POWER OF BUYERS	97
5.11.5	INTENSITY OF COMPETITIVE RIVALRY	97
5.12	PATENT ANALYSIS	97
5.12.1	PATENT PUBLICATION TRENDS	97
5.12.2	JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR AI IN PRECISION MEDICINE	98
5.12.3	KEY PATENTS IN AI IN PRECISION MEDICINE MARKET	99
5.13	KEY STAKEHOLDERS AND BUYING CRITERIA	102
5.13.1	KEY STAKEHOLDERS IN BUYING PROCESS	102
5.13.2	KEY BUYING CRITERIA	103
5.14	END-USER ANALYSIS	104
5.14.1	UNMET NEEDS	104
5.14.2	END-USER EXPECTATIONS	105
5.15	KEY CONFERENCES & EVENTS	106
5.16	CASE STUDY ANALYSIS	107
5.16.1	SANOFI LEVERAGED AI-DRIVEN PRECISION MEDICINE TO IDENTIFY PATIENT SUBTYPES AND NOVEL TARGETS IN	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

INFLAMMATORY BOWEL DISEASE 107

5.16.2 IBM'S AI-DRIVEN SOLUTION IMPROVED CLINICAL TRIAL ENROLLMENT AT MAYO CLINIC BY ENHANCING PATIENT MATCHING 108

5.16.3 ENHANCING PATIENT IDENTIFICATION FOR RARE ONCOLOGY BIOMARKERS THROUGH GENOMIC TESTING AND STRATEGIC COLLABORATION 108

5.17 INVESTMENT AND FUNDING SCENARIO 109

5.18 BUSINESS MODELS 109

5.19 IMPACT OF AI/GEN AI IN PRECISION MEDICINE MARKET 111

5.19.1 KEY USE CASES 112

5.19.2 CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION 112

5.19.2.1 Enhancing patient outcomes with AI-driven predictive analytics at Johns Hopkins Hospital 112

5.19.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 113

5.19.3.1 AI in drug discovery market 113

5.19.3.2 Genomics market 113

5.19.3.3 Artificial intelligence market 114

5.19.3.4 Pharmacogenomics market 114

5.19.4 USER READINESS AND IMPACT ASSESSMENT 114

5.19.4.1 User readiness 114

5.19.4.1.1 Healthcare providers 114

5.19.4.1.2 Pharmaceutical & biotechnology companies 114

6 ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY APPLICATION 115

6.1 INTRODUCTION 116

6.2 DRUG DISCOVERY & DEVELOPMENT 116

6.2.1 DRUG DISCOVERY 117

6.2.2 UNDERSTANDING DISEASES 117

6.2.2.1 Rise in data mining to link targets to diseases 117

6.2.3 DRUG REPURPOSING 118

6.2.3.1 Use of graphs for targeted approach to reduce timelines and costs 118

6.2.4 DE NOVO DRUG DESIGN 119

6.2.4.1 Availability of large-scale biomedical datasets and urgent demand for novel treatments for complex diseases 119

6.2.5 DRUG OPTIMIZATION 120

6.2.5.1 Need to process extensive data on molecular properties, target interactions, and clinical outcomes 120

6.2.6 SAFETY & TOXICITY 121

6.2.6.1 Building generalizable model for toxicity and off-target effect prediction 121

6.2.7 CLINICAL DEVELOPMENT 122

6.2.7.1 Designing and conducting clinical trials for personalized dosing, targeted therapies 122

6.3 DIAGNOSTICS & SCREENING 124

6.3.1 RISK ASSESSMENT & PATIENT STRATIFICATION 124

6.3.1.1 Leveraging AI to personalize treatment plan 124

6.3.2 DISEASE SCREENING 125

6.3.2.1 Leveraging machine learning to peruse and resolve complex patient data 125

6.3.3 DISEASE DIAGNOSIS 126

6.3.3.1 Identifying biomarkers for precise treatment 126

6.3.4 DISEASE PROGRESSION, STAGING, AND PROGNOSIS 127

6.3.4.1 Using AI to track disease conditions 127

?

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6.4	THERAPEUTICS	128
6.4.1	THERAPY SELECTION & PLANNING	129
6.4.1.1	Leveraging generative models to predict and design suitable treatment	129
6.4.2	THERAPY MONITORING	130
6.4.2.1	Need to effectively track safety and efficacy of treatment	130
6.4.3	POST-TREATMENT SURVEILLANCE & FOLLOW-UP	131
6.4.3.1	AI algorithms to identify subtle patterns in data, allowing for early detection of potential issues	131
7	ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY THERAPEUTIC AREA	133
7.1	INTRODUCTION	134
7.2	ONCOLOGY	134
7.2.1	HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS	134
7.3	RARE DISEASES	136
7.3.1	COMBATING CHALLENGING THERAPEUTICS DUE TO COMPLEX AND HETEROGENEOUS NATURE OF RARE DISEASES	136
7.4	INFECTIOUS DISEASES	137
7.4.1	NEED FOR INNOVATION IN INFECTIOUS DISEASE TREATMENT, ESPECIALLY AFTER IMPACT OF COVID-19	137
7.5	NEUROLOGY	139
7.5.1	SHORTAGE AND COMPLEXITY OF NEURODEGENERATIVE DISEASES	139
7.6	CARDIOLOGY	141
7.6.1	WIDE RANGE AND INCIDENCE OF CARDIOVASCULAR DISEASES	141
7.7	HEMATOLOGY	142
7.7.1	AI-DRIVEN ALGORITHMS TO ANALYZE BLOOD SAMPLES, IMAGING DATA, AND GENOMIC PROFILES TO DETECT ABNORMALITIES	142
7.8	OTHER THERAPEUTIC AREAS	143
8	ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY COMPONENT	145
8.1	INTRODUCTION	146
8.2	SOFTWARE	146
8.2.1	SCALABILITY AND FLEXIBILITY OF AI SOFTWARE TO ENHANCE EFFICIENCY OF CLINICAL WORKFLOWS	146
8.3	SERVICES	148
8.3.1	NEED FOR EXPERT ASSISTANCE AMONG HEALTHCARE ORGANIZATIONS IN ADOPTING AND OPTIMIZING AI TECHNOLOGIES	148
9	AI IN PRECISION MEDICINE MARKET, BY TOOL	150
9.1	INTRODUCTION	151
9.2	MACHINE LEARNING	151
9.2.1	DEEP LEARNING	153
9.2.1.1	Convolutional neural networks	154
9.2.1.1.1	Interpreting complex biological data to enable personalizing healthcare	154
9.2.1.2	Recurrent neural networks (RNNs)	155
9.2.1.2.1	Optimizing clinical data to model patient trajectories by analyzing longitudinal data	155
9.2.1.3	Generative adversarial networks (GANs)	156
9.2.1.3.1	GAN to focus on new molecules and biological datasets	156
9.2.1.4	Graph neural networks (GNNs)	157
9.2.1.4.1	Predicting drug-drug interactions to optimize personalized treatment	157
9.2.1.5	Other deep learning tools	158
9.2.2	SUPERVISED MACHINE LEARNING	158
9.2.3	REINFORCEMENT MACHINE LEARNING	159

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

9.2.4	UNSUPERVISED MACHINE LEARNING	160
9.2.5	OTHER MACHINE LEARNING TOOLS	161
9.3	NATURAL LANGUAGE PROCESSING	162
9.3.1	ABUNDANCE OF UNSTRUCTURED DATA IN CLINICAL RESEARCH TO BE INTERPRETED	162
9.4	CONTEXT-AWARE PROCESSING & COMPUTING	163
9.4.1	TAILORING PATIENT CARE IN REAL TIME TO ENHANCE PRECISION MEDICINE	163
9.5	COMPUTER VISION	164
9.5.1	INCREASE IN USE OF IMAGING BIOMARKERS TO SUPPORT SURGICAL PRECISION	164
9.6	IMAGE ANALYSIS	165
9.6.1	HARNESSING MACHINE LEARNING TO AUTOMATE TECHNIQUES SUCH AS QUANTITATIVE IMAGING AND RADIOMICS	165
9.7	OTHER TOOLS	166
10	ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY DEPLOYMENT	168
10.1	INTRODUCTION	169
10.2	CLOUD-BASED MODEL	169
10.2.1	RESEARCH COLLABORATION AND COST-EFFICIENCY OF CLOUD DEPLOYMENT	169
10.3	ON-PREMISE MODEL	171
10.3.1	EASIER TO SECURE PATIENT DATA AND ENSURE COMPLIANCE IN ON-PREMISE AI-DRIVEN PRECISION MEDICINE	171
10.4	HYBRID MODEL	172
10.4.1	HYBRID MODELS TO ENHANCE FLEXIBILITY AND SECURITY	172
11	ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY END USER	174
11.1	INTRODUCTION	175
11.2	HEALTHCARE PROVIDERS	175
11.2.1	REVOLUTIONIZING PATIENT CARE AND TREATMENT DELIVERY THROUGH ADVANCED TECHNOLOGIES	175
11.3	PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES	176
11.3.1	DRIVING DRUG DEVELOPMENT EFFICIENCY TO DESIGN ADAPTIVE TRIAL PROTOCOLS AND OPTIMIZE TREATMENT	176
11.4	MEDICAL DEVICE & EQUIPMENT COMPANIES	177
11.4.1	INTEGRATION OF AI IN MEDICAL DEVICES TO ENHANCE PRECISION AND PERSONALIZED HEALTHCARE	177
11.5	RESEARCH CENTERS, ACADEMIC INSTITUTES, AND GOVERNMENT ORGANIZATIONS	178
11.5.1	AI IN ACADEMIC INSTITUTES AND PUBLIC SECTOR COLLABORATIONS TO ACCELERATE INNOVATION AND RESEARCH	178
11.6	OTHER END USERS	179
12	ARTIFICIAL INTELLIGENCE IN PRECISION MEDICINE MARKET, BY REGION	181
12.1	INTRODUCTION	182
12.2	NORTH AMERICA	182
12.2.1	NORTH AMERICA: MACROECONOMIC OUTLOOK	183
12.2.2	US	187
12.2.2.1	US to dominate North American market with advanced regulatory system	187
12.2.3	CANADA	190
12.2.3.1	Emergence of new AI-based startups and high health expenditure	190
12.3	EUROPE	194
12.3.1	EUROPE: MACROECONOMIC OUTLOOK	194
12.3.2	UK	198
12.3.2.1	Favorable government R&D investment and collaborations focused on drug discovery	198
12.3.3	GERMANY	201
12.3.3.1	Growing R&D investment by pharma and biotech companies	201
12.3.4	FRANCE	204
12.3.4.1	Strong government support through investments in initiatives	204

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.3.5	ITALY	208
12.3.5.1	Government Initiatives addressing local healthcare challenges through studies aimed at broader precision medicine strategies	208
12.3.6	SPAIN	211
12.3.6.1	High investments by pharmaceutical companies	211
12.3.7	REST OF EUROPE	214
12.4	ASIA PACIFIC	217
12.4.1	ASIA PACIFIC: MACROECONOMIC OUTLOOK	217
12.4.2	JAPAN	222
12.4.2.1	High investment in R&D and government initiatives focused on treatment outcomes	222
12.4.3	CHINA	226
12.4.3.1	Government funding to advance data analysis and international collaborations to develop targeted therapies	226
12.4.4	INDIA	229
12.4.4.1	High growth of pharmaceutical and medical device industries	229
12.4.5	REST OF ASIA PACIFIC	233
12.5	LATIN AMERICA	236
12.5.1	LATIN AMERICA: MACROECONOMIC OUTLOOK	236
12.5.2	BRAZIL	240
12.5.2.1	Increase in governmental support through initiatives such as Brazilian Artificial Intelligence Plan	240
12.5.3	MEXICO	243
12.5.3.1	High potential to become leader in terms of readiness in technology	243
12.5.4	REST OF LATIN AMERICA	246
12.6	MIDDLE EAST & AFRICA	249
12.6.1	MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK	249
12.6.2	GCC COUNTRIES	253
12.6.2.1	Increasing emphasis on personalized medicines and developing healthcare infrastructure	253
12.6.3	REST OF MIDDLE EAST & AFRICA	257
13	COMPETITIVE LANDSCAPE	261
13.1	INTRODUCTION	261
13.2	KEY PLAYER STRATEGY/RIGHT TO WIN	261
13.3	REVENUE ANALYSIS, 2019?2023	264
13.4	MARKET SHARE ANALYSIS, 2023	265
13.4.1	RANKING OF KEY MARKET PLAYERS	267
13.5	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023	268
13.5.1	STARS	268
13.5.2	EMERGING LEADERS	268
13.5.3	PERVASIVE PLAYERS	268
13.5.4	PARTICIPANTS	268
13.5.5	COMPANY FOOTPRINT: KEY PLAYERS, 2023	270
13.5.5.1	Company footprint	270
13.5.5.2	Therapeutic area footprint	271
13.5.5.3	End user footprint	272
13.5.5.4	Component footprint	273
13.5.5.5	Deployment footprint	274
13.5.5.6	Region footprint	275
?		
13.6	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023	276

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.6.1	PROGRESSIVE COMPANIES	276
13.6.2	RESPONSIVE COMPANIES	276
13.6.3	DYNAMIC COMPANIES	276
13.6.4	STARTING BLOCKS	276
13.6.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023	278
13.6.5.1	Detailed list of key startup/SME players	278
13.6.5.2	Competitive benchmarking of key emerging players/startups, by region	279
13.7	COMPANY VALUATION AND FINANCIAL METRICS	279
13.7.1	COMPANY VALUATION	279
13.7.2	FINANCIAL METRICS	280
13.8	BRAND/PRODUCT COMPARISON	281
13.9	COMPETITIVE SCENARIO	282
13.9.1	PRODUCT LAUNCHES	282
13.9.2	DEALS	283
13.9.3	EXPANSIONS	285
13.9.4	OTHER DEVELOPMENTS	286
14	COMPANY PROFILES	287
14.1	KEY PLAYERS	287
14.1.1	NVIDIA CORPORATION	287
14.1.1.1	Business overview	287
14.1.1.1.2	Products/Services/Solutions offered	289
14.1.1.1.3	Recent developments	289
14.1.1.1.3.1	Product launches	289
14.1.1.1.3.2	Deals	291
14.1.1.1.4	MnM view	295
14.1.1.1.4.1	Right to win	295
14.1.1.1.4.2	Strategic choices	295
14.1.1.1.4.3	Weaknesses & competitive threats	295
14.1.2	EXSCIENTIA	296
14.1.2.1	Business overview	296
14.1.2.2	Products/Services/Solutions offered	297
14.1.2.3	Recent developments	298
14.1.2.3.1	Product launches	298
14.1.2.3.2	Deals	298
14.1.2.3.3	Expansions	303
14.1.2.3.4	Other developments	304
14.1.2.4	MnM view	305
14.1.2.4.1	Right to win	305
14.1.2.4.2	Strategic choices	305
14.1.2.4.3	Weaknesses and competitive threats	306
14.1.3	GOOGLE	307
14.1.3.1	Business overview	307
14.1.3.2	Products/Services/Solutions offered	309
14.1.3.3	Recent developments	309
14.1.3.3.1	Product launches	309
14.1.3.3.2	Deals	310
14.1.3.3.3	Expansions	311

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.1.3.4	MnM view	311
14.1.3.4.1	Right to win	311
14.1.3.4.2	Strategic choices	311
14.1.3.4.3	Weaknesses and competitive threats	312
14.1.4	ILLUMINA, INC.	313
14.1.4.1	Business overview	313
14.1.4.2	Products/Services/Solutions offered	314
14.1.4.3	Recent developments	315
14.1.4.3.1	Product launches	315
14.1.4.3.2	Deals	316
14.1.4.4	MnM view	317
14.1.4.4.1	Right to win	317
14.1.4.4.2	Strategic choices	317
14.1.4.4.3	Weaknesses and competitive threats	317
14.1.5	TEMPUS AI, INC.	318
14.1.5.1	Business overview	318
14.1.5.2	Products/Services/Solutions offered	318
14.1.5.3	Recent developments	319
14.1.5.3.1	Product launches	319
14.1.5.3.2	Deals	320
14.1.5.3.3	Expansions	323
14.1.5.3.4	Other developments	324
14.1.5.4	MnM view	324
14.1.5.4.1	Right to win	324
14.1.5.4.2	Strategic choices	324
14.1.5.4.3	Weaknesses and competitive threats	324
14.1.6	BENEVOLENTAI	325
14.1.6.1	Business overview	325
14.1.6.2	Products/Services/Solutions offered	326
14.1.6.3	Recent developments	326
14.1.6.3.1	Deals	326
14.1.7	MICROSOFT CORPORATION	329
14.1.7.1	Business overview	329
14.1.7.2	Products/Services/Solutions offered	331
14.1.7.3	Recent developments	331
14.1.7.3.1	Deals	331
14.1.8	IBM	334
14.1.8.1	Business overview	334
14.1.8.2	Products/Services/Solutions offered	336
14.1.8.3	Recent developments	336
14.1.8.3.1	Deals	336
14.1.9	GE HEALTHCARE	337
14.1.9.1	Business overview	337
14.1.9.2	Products/Services/Solutions offered	338
14.1.9.3	Recent developments	339
14.1.9.3.1	Product launches	339
14.1.9.3.2	Deals	340

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.1.9.3.3	Other developments	341
14.1.10	DEEP GENOMICS	342
14.1.10.1	Business overview	342
14.1.10.2	Products/Services/Solutions offered	342
14.1.10.3	Recent developments	343
14.1.10.3.1	Product launches	343
14.1.10.3.2	Deals	343
14.1.10.3.3	Other developments	343
14.1.11	SIEMENS HEALTHINEERS AG	344
14.1.11.1	Business overview	344
14.1.11.2	Products/Solutions/Services offered	345
14.1.11.3	Recent developments	346
14.1.11.3.1	Deals	346
14.1.12	BIOXCEL THERAPEUTICS, INC.	347
14.1.12.1	Business overview	347
14.1.12.2	Products/Solutions/Services offered	347
14.1.12.3	Recent developments	348
14.1.12.3.1	Deals	348
14.1.12.3.2	Other developments	348
14.1.13	INSILICO MEDICINE	349
14.1.13.1	Business overview	349
14.1.13.2	Products/Services/Solutions offered	350
14.1.13.3	Recent developments	350
14.1.13.3.1	Product launches	350
14.1.13.3.2	Deals	352
14.1.13.3.3	Other developments	356
14.1.14	PATHAI, INC.	358
14.1.14.1	Business overview	358
14.1.14.2	Products/Services/Solutions offered	359
14.1.14.3	Recent developments	360
14.1.14.3.1	Product launches	360
14.1.14.3.2	Deals	362
14.1.14.3.3	Other developments	364
14.1.15	VERGE GENOMICS	365
14.1.15.1	Business overview	365
14.1.15.2	Products/Services/Solutions offered	365
14.1.15.3	Recent developments	366
14.1.15.3.1	Deals	366
14.1.16	GUARDANT HEALTH, INC.	367
14.1.16.1	Business overview	367
14.1.16.2	Products/Services/Solutions offered	368
14.1.16.3	Recent developments	369
14.1.16.3.1	Product launches	369
14.1.16.3.2	Deals	370
14.1.16.3.3	Other developments	372
14.1.17	GRAIL, INC.	374
14.1.17.1	Business overview	374

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.1.17.2	Products/Services/Solutions offered	374
14.1.17.3	Recent developments	375
14.1.17.3.1	Deals	375
14.1.18	FOUNDATION MEDICINE, INC.	377
14.1.18.1	Business overview	377
14.1.18.2	Products/Services/Solutions offered	377
14.1.18.3	Recent developments	378
14.1.18.3.1	Deals	378
14.1.18.3.2	Other developments	380
14.1.19	PROSCIA INC.	382
14.1.19.1	Business overview	382
14.1.19.2	Products/Services/Solutions offered	382
14.1.19.3	Recent developments	383
14.1.19.3.1	Product launches	383
14.1.19.3.2	Deals	383
14.1.19.3.3	Other developments	384
14.1.20	FLATIRON HEALTH	385
14.1.20.1	Business overview	385
14.1.20.2	Products/Services/Solutions offered	385
14.1.20.3	Recent developments	386
14.1.20.3.1	Deals	386
14.1.20.3.2	Other developments	387
?		
14.2	OTHER PLAYERS	388
14.2.1	PREDICTIVE ONCOLOGY	388
14.2.2	PAIGE AI, INC.	389
14.2.3	DENSITAS INC.	390
14.2.4	ZEPHYR AI, INC.	391
14.2.5	NUCLEAI, INC.	392
15	APPENDIX	393
15.1	DISCUSSION GUIDE	393
15.2	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	399
15.3	CUSTOMIZATION OPTIONS	401
15.4	RELATED REPORTS	401
15.5	AUTHOR DETAILS	402

AI in Precision Medicine Market by Application (Drug Discovery, Screening, Diagnosis, Stratification, Staging, Prognosis, Therapy Selection, Monitoring, Risk Management), Indication (Cancer, CNS, CVS), Tools (ML, NLP), & End User -Global Forecast to 2030

Market Report | 2024-12-02 | 403 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

Signature